Physician profile
Nkiru Smith
NPI 1205332814
$4,921.28
in general payments reported to CMS, 2019-2025
22 companies · $2,096 in 2025
The $2,096 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.81 · 2022: $199 · 2023: $980 · 2024: $1,598 · 2025: $2,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,654 · Education: $21.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,653.72 |
| Education | $21.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,076.68 | 2023-2025 | Caplyta |
| Gilead Sciences, INC. | $615.53 | 2023-2025 | Epclusa |
| Abbvie INC. | $498.94 | 2024-2025 | |
| Alkermes, INC. | $470.35 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Indivior INC. | $381.08 | 2022-2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $252.93 | 2023 | Spravato |
| Vanda Pharmaceuticals INC. | $231.38 | 2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $231.04 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $205.02 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $175.99 | 2025 | Rexulti |
| Novo Nordisk INC | $100.80 | 2022 | |
| Boston Scientific Corporation | $100.26 | 2023 | Wavewriter Alpha Prime 16 |
| Braeburn INC. | $96.25 | 2024 | Brixadi |
| Orexo US, INC. | $90.51 | 2021-2025 | Zubsolv |
| Shield Therapeutics INC | $84.40 | 2023 | Accrufer |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $76.07 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $70.30 | 2024-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $55.04 | 2025 | Rexulti |
| Biogen, INC. | $40.42 | 2022 | |
| Corium, LLC | $27.28 | 2024 | Azstarys |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Lilly USA, LLC | $20.01 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nkiru Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.